Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients fulfilling the following criteria at Screening are eligible for participation in the study:~1. Age 13 years or older~2. Laboratory confirmed diagnosis of HAE~3. A history of frequent HAE attacks (at least 4 attacks per month across a minimum of 3 consecutive months).~4. Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception.~5. Provided written informed consent (and written assent for minors)~6. Willingness and ability to comply with all protocol procedures~Exclusion Criteria:~Patients who meet any of the following criteria at Screening are to be excluded from study participation:~1. Patients with medical history of allergy to rabbits or rabbit-derived products (including rhC1INH)~2. Diagnosis of acquired angioedema (AAE)~3. Patients who are pregnant, or breastfeeding, or are currently intending to become pregnant~4. Treatment with any investigational drug in the past 30 days~5. Patients with any condition or treatment that, in the opinion of the Investigator, might interfere with the evaluation of study objectives~6. Patients currently treated with angiotensin-converting enzyme (ACE) inhibitors

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhC1INH twice weekly (Type: EXPERIMENTAL): rhC1INH administered twice weekly
- rhC1INH once weekly (Type: EXPERIMENTAL): rhC1INH administered once weekly
- Placebo (Saline) twice weekly (Type: PLACEBO_COMPARATOR): Placebo (Saline) administered twice weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).